Oral Nimodipine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights

Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMike moyerW taylor kimberlyPrashant kohliBoard of directors the companyNeurocritical care society annual meetingSecurities exchangeExchange commissionCompany classDrug administrationAcasti pharma incNeurocritical care societyAnnounces second quarterFirst patientPrivate placement equity financingDrug application

Acasti Pharma Inc Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol

Acasti Pharma Inc. announced that the Company has aligned with the U.S. Food and Drug Administration on the protocol for its pivotal Phase 3 trial of GTX-104 and the FDA also provided guidance for a.

United statesAcasti pharma incDrug administrationAcasti pharmaDrug applicationOral nimodipineOrphan drug designationSubarachnoid hemorrhage

Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

STRIVE-ON is the pivotal Phase 3 trial of GTX-104 to evaluate its comparable safety and tolerability profile relative to oral nimodipine in patients hospitalized with aSAH GTX-104 has been.

United statesRobert blumPrashant kohliCompany nasdaqLytham partnersSecurities exchangePrnewswire acasti pharma incDrug administrationExchange commissionAcasti pharma incDrug applicationOral nimodipineSubarachnoid hemorrhageIntensive care unitOrphan drug designationSecurities litigation reform act